PT3044206T - (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro - Google Patents

(3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro

Info

Publication number
PT3044206T
PT3044206T PT147441042T PT14744104T PT3044206T PT 3044206 T PT3044206 T PT 3044206T PT 147441042 T PT147441042 T PT 147441042T PT 14744104 T PT14744104 T PT 14744104T PT 3044206 T PT3044206 T PT 3044206T
Authority
PT
Portugal
Prior art keywords
oxitocin
methyloxin
ona
pyrrolidin
premature
Prior art date
Application number
PT147441042T
Other languages
English (en)
Portuguese (pt)
Inventor
Chollet Andre
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of PT3044206T publication Critical patent/PT3044206T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT147441042T 2013-09-10 2014-07-25 (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro PT3044206T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13183723.9A EP2845850A1 (en) 2013-09-10 2013-09-10 Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

Publications (1)

Publication Number Publication Date
PT3044206T true PT3044206T (pt) 2018-05-09

Family

ID=49118429

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147441042T PT3044206T (pt) 2013-09-10 2014-07-25 (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro

Country Status (22)

Country Link
US (7) US20160221944A1 (enExample)
EP (4) EP2845850A1 (enExample)
JP (7) JP2016529258A (enExample)
KR (3) KR101907338B1 (enExample)
CN (4) CN109928905A (enExample)
AU (3) AU2014320694B2 (enExample)
BR (1) BR112016005276B1 (enExample)
CA (2) CA2921580C (enExample)
CY (1) CY1120152T1 (enExample)
DK (1) DK3044206T3 (enExample)
EA (2) EA036830B1 (enExample)
ES (2) ES2664403T3 (enExample)
HU (1) HUE037578T2 (enExample)
IL (2) IL244152A (enExample)
MX (1) MX370602B (enExample)
PT (1) PT3044206T (enExample)
SG (2) SG11201601743RA (enExample)
SI (1) SI3044206T1 (enExample)
TR (1) TR201807175T4 (enExample)
UA (1) UA115708C2 (enExample)
WO (1) WO2015036160A1 (enExample)
ZA (1) ZA201704072B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EA201891873A1 (ru) 2014-07-02 2019-04-30 Обсева Са Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r
CA3009576A1 (en) 2016-01-04 2017-07-13 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
CA3019662A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of California Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists
EP4541348A3 (en) * 2016-04-12 2025-06-04 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
WO2018015497A2 (en) * 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN114667141A (zh) 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
RU2756027C1 (ru) * 2021-02-24 2021-09-24 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ диагностики наружного генитального эндометриоза
AU2023353578A1 (en) * 2022-09-30 2025-03-20 Ferring B.V. Mixed vasopressin receptor agonist-antagonist for treating end-stage liver disease and complications associated thereof
TW202435864A (zh) * 2023-02-09 2024-09-16 大陸商上海葆正醫藥科技有限公司 亞胺化合物及其製備方法和應用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482815A (en) 1967-07-07 1969-12-09 Victor Naturale Collapsible core for a mold
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US4832307A (en) 1988-09-15 1989-05-23 Toshiba Kikai Kabushiki Kaisha Injection mold
YU183988A (en) 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
JP2927532B2 (ja) * 1989-11-09 1999-07-28 塩野義製薬株式会社 含窒素異項環オキシーフェノキシ酢酸誘導体およびその除草剤としての用途
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP2869854B2 (ja) 1994-10-19 1999-03-10 株式会社トスカ 合成樹脂の成形方法とその装置
JP3534903B2 (ja) * 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2263510T3 (es) 1999-12-09 2006-12-16 Reckitt Benckiser Healthcare (Uk) Limited Preparacion en comprimidos que comprende un antiinflamatorio no esteroideo (aine).
JP2003528854A (ja) 2000-03-27 2003-09-30 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 医薬として活性なピロリジン誘導体
ES2262640T3 (es) 2000-03-27 2006-12-01 Applied Research Systems Ars Holding N.V. Derivados de pirrolidina farmaceuticamente activos como inhibidores de bax.
JP4350948B2 (ja) 2001-03-20 2009-10-28 ラボラトワール セローノ ソシエテ アノニム オキシトシン調節活性を有するピロリジンエステル誘導体
HRP20031017A2 (en) 2001-06-18 2004-04-30 Applied Research Systems Pyrrolidine oxasidiazole- and thiadiazole derivatives
JP2003192582A (ja) 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
DE602004024170D1 (de) 2003-02-27 2009-12-31 Merck Serono Sa Coinsins Pyrrolidin-derivate als oxytocin antagonisten
CN1946686A (zh) * 2004-02-26 2007-04-11 应用研究系统Ars股份公司 制备吡咯烷肟的方法
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
WO2006121362A2 (en) 2005-05-10 2006-11-16 Ferring International Center Sa. Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
JP2008189732A (ja) * 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
US20090152770A1 (en) 2007-08-07 2009-06-18 Canon Virginia Inc. Mechanically collapsible core for injection molding
BRPI0817927A2 (pt) 2007-10-01 2015-04-07 Lesvi Laboratorios Sl Comprimidos orodispersiveis
WO2009146013A1 (en) * 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
HK1213454A1 (zh) 2012-11-26 2016-07-08 Ferring B.V. 使用图像分析诊断子宫收缩水平的方法和系统
JP5942815B2 (ja) 2012-11-26 2016-06-29 株式会社ジェイテクト 等速ジョイント用ブーツの成形金型
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EA201891873A1 (ru) 2014-07-02 2019-04-30 Обсева Са Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Also Published As

Publication number Publication date
KR101907338B1 (ko) 2018-10-11
MX2016003042A (es) 2016-06-10
JP2025128177A (ja) 2025-09-02
CA2979461A1 (en) 2015-03-19
AU2019201859A1 (en) 2019-04-11
CY1120152T1 (el) 2018-12-12
KR101749877B1 (ko) 2017-06-21
US20170240508A1 (en) 2017-08-24
KR101804739B1 (ko) 2017-12-05
CN105531259A (zh) 2016-04-27
IL254246A0 (en) 2017-10-31
US20210047266A1 (en) 2021-02-18
KR20170054553A (ko) 2017-05-17
IL244152A (en) 2017-09-28
US20240228439A1 (en) 2024-07-11
SG10201800624SA (en) 2018-03-28
MX370602B (es) 2019-12-18
AU2018201730A1 (en) 2018-04-05
AU2018201730B2 (en) 2019-01-03
JP6462030B2 (ja) 2019-01-30
AU2014320694A1 (en) 2016-04-21
CN107674011A (zh) 2018-02-09
WO2015036160A1 (en) 2015-03-19
JP2023182673A (ja) 2023-12-26
US10604482B2 (en) 2020-03-31
US9670155B2 (en) 2017-06-06
US20160221944A1 (en) 2016-08-04
EP3044206B1 (en) 2018-02-28
US20180215708A1 (en) 2018-08-02
UA115708C2 (uk) 2017-12-11
ES2664403T3 (es) 2018-04-19
EP3044206A1 (en) 2016-07-20
JP2018150376A (ja) 2018-09-27
IL244152A0 (en) 2016-04-21
EA036830B1 (ru) 2020-12-24
DK3044206T3 (en) 2018-05-28
EA202092300A1 (ru) 2021-06-30
US20150073032A1 (en) 2015-03-12
SG11201601743RA (en) 2016-04-28
KR20170133525A (ko) 2017-12-05
US10047048B2 (en) 2018-08-14
ES2914776T3 (es) 2022-06-16
CN109928905A (zh) 2019-06-25
CA2979461C (en) 2021-08-31
CN109748836A (zh) 2019-05-14
HK1247612A1 (en) 2018-09-28
EP3252037B1 (en) 2022-03-09
US20230097933A1 (en) 2023-03-30
AU2014320694B2 (en) 2017-12-14
HUE037578T2 (hu) 2018-09-28
TR201807175T4 (tr) 2018-06-21
ZA201704072B (en) 2018-08-29
US11312683B2 (en) 2022-04-26
JP2016529258A (ja) 2016-09-23
CA2921580C (en) 2017-11-14
CA2921580A1 (en) 2015-03-19
HK1221716A1 (en) 2017-06-09
SI3044206T1 (en) 2018-05-31
BR112016005276B1 (pt) 2022-10-18
JP2017141281A (ja) 2017-08-17
JP2020015728A (ja) 2020-01-30
JP6659078B2 (ja) 2020-03-04
EP4129979A1 (en) 2023-02-08
KR20160053990A (ko) 2016-05-13
AU2019201859B2 (en) 2019-11-21
JP2021193084A (ja) 2021-12-23
EA201690480A1 (ru) 2016-08-31
IL254246B (en) 2019-08-29
EP3252037A1 (en) 2017-12-06
EP2845850A1 (en) 2015-03-11
BR112016005276A2 (enExample) 2017-08-01

Similar Documents

Publication Publication Date Title
PT3044206T (pt) (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro
LT3010910T (lt) Pirimidindiono junginiai, skirti širdies ligoms
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
IL246025B (en) Formulations for neoplasia vaccines
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
EP2812004A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EA201691853A1 (ru) Агонисты мускариновых рецепторов
LT2959005T (lt) Medicininis naudojimas, susijęs su telomerų ilgėjimu
BR302012006140S1 (pt) Configuração aplicada a quadro branco.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
LT3532486T (lt) Prie antikūno prijungti ciklinio peptido-tirozino-tirozino junginiai kaip neuropeptido y receptorių moduliatoriai
CL2015001014A1 (es) Composicion de silicato de zirconio microporoso, util para el tratamiento de la hipercalemia
IL245471B (en) Fluorinated compounds as alpha v integrin receptor antagonists
EP3322311A4 (en) EXOTHERMIC EVAPORATOR
MX387228B (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos.
IL245647A0 (en) surgical gauze
DK3524230T3 (da) Farmakologiske formuleringer, der omfatter ccr3-antagonister
EP3016944A4 (en) COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS
FR2998173B1 (fr) Extrait de garcinia kola, utilisation pour son action anti-glycation
EP2934519A4 (en) THERAPEUTIC THIAZOLIDINONE COMPOUNDS
EP2953470A4 (en) 2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
CO7010832A2 (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
LT3044223T (lt) 2,3-dihidro-1h-inden-1-ono dariniai, kaip su retinoine rūgštimi susijusio orfaninio receptoriaus gama (ror-gama) antagonistai, skirti išsėtinės sklerozės gydymui
BR112017017317A2 (pt) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4- (etoxioxalilamino)-2-hidroximetil-2-metilpentanóico como inibidor de neprilisina
IL245996A0 (en) A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder